EGFR-Mutant NSCLC: Second-Line Treatment Options and Safety Data

Osimertinib plus chemotherapy significantly improved overall survival in EGFR-mutated NSCLC, outperforming monotherapy across various prognostic factors.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Alectinib shows promising long-term survival benefits over crizotinib for advanced ALK-positive NSCLC, highlighting significant clinical advancements.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Results from the Beamion LUNG-1 study showed that first-line zongertinib yielded continued benefit for patients with HER2-mutated NSCLC.

The safety profile of durvalumab after radiotherapy was consistent with durvalumab after chemoradiotherapy among those with unresectable stage III NSCLC.